Source: Annual Congress 2002 - Thoracic oncology: biology
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
C. Mascaux, B. Martin, A. P. Meert, J. M. Verdebout, M. Paesmans, V. Ninane, J. P. Sculier (Brussels, Belgium). Expression of Fhit protein in non-small cell lung cancer (NSCLC) and its correlation with Ki-67, a proliferative marker. Eur Respir J 2002; 20: Suppl. 38, 1505

Member's Comments

No comment yet.

Related content which might interest you: The expression of Ki-67, a marker of proliferative activity, in resected nonsmall cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 478s Year: 2001 The prognostic value of altered pRb and p53 protein expression in non-small cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 363s Year: 2003 Prognostic value of p21 protein expression in non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 674s Year: 2004 p53 and mdm2 expression in nonsmall cell lung cancer (NSCLC): the lack of prognostic relevance Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001 Nuclear expression of Y-Box binding protein (YB-1) as a negative prognostic marker in non-small cell lung cancer Source: Annual Congress 2003 - Lung cancer biology Year: 2003 Survivin expression in non-small cell lung cancer Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010 Ki-67 in non-small cell lung cancer Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease Year: 2012 Prognostic value of ERCC1 expression in advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 Prognostic significance of S-100 immmunostaining in non-small cell lung cancer (NSCLC) Source: Annual Congress 2004 - Prognostic factors Year: 2004 Expression of Her-2/neu and Bcl-2 in patients with non-small cell lung cancer Source: International Congress 2017 – Gene signatures in bronchial diseases Year: 2017 p-53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer Source: Annual Congress 2007 - Novel genetic markers in pathology Year: 2007 The association of p53 and p21 expression with clinicopathological parameters and prognosis in non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 The value of CD44 and MMP-2 expression in non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 77s Year: 2004 HER-2/neu oncoprotein expression in nonsmall cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002 Expression and significance of VE-cadherin and E-cadherin in non-small cell lung cancer Source: Annual Congress 2011 - Progress in pathology of lung cancer Year: 2011 Investigation of survivin gene polymorphism in non-small cell lung cancer patients (NSCLC) Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 Prognostic significance of p53 and bcl-2 abnormalities in operable non-small cell lung cancer Source: Eur Respir J 2001; 17: 660-666 Year: 2001 Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status Source: Annual Congress 2011 - Epidemiology of lung cancer and screening Year: 2011 FGFR1 gene aberrations and FGFR1 protein expression in squamous non-small cell lung cancer (Sq-NSCLC). Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research Year: 2021 Fragile histidine triad protein expression in nonsmall cell lung cancer and correlation with Ki-67 and with p53 Source: Eur Respir J 2003; 21: 753-758 Year: 2003